LONDON — Bad idea. Analysts covering Unilever didn’t hold back their feelings about the group’s 50-billion-pound bid for the consumer health care division of GlaxoSmithKline, which emerged over the we...
LONDON — Bad idea. Analysts covering Unilever didn’t hold back their feelings about the group’s 50-billion-pound bid for the consumer health care division of GlaxoSmithKline, which emerged over the we...